GO:0097006 regulation of plasma lipoprotein particle levels: Lipid Homeostasis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097006 describes any biological process that maintains the internal levels of plasma lipoprotein particles, including their assembly, secretion, remodeling, and clearance.
• The term encompasses the regulation of VLDL, LDL, HDL, and Lp(a) particles, which are central to lipid transport and cardiovascular health.
• Key molecular players include apolipoproteins (APOB, APOA1, APOE), lipid transfer proteins (CETP, PLTP), receptors (LDLR, SR-B1), and enzymes (LPL, LCAT).
• Dysregulation of plasma lipoprotein levels is a hallmark of atherosclerosis, nephrotic syndrome, obesity, and other metabolic disorders.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of genes controlling lipoprotein metabolism.
• Understanding this process guides therapeutic strategies targeting LDL cholesterol, HDL function, and Lp(a) to reduce cardiovascular risk.
Description
Plasma lipoprotein particles are macromolecular assemblies that transport lipids through the bloodstream, and their levels are tightly regulated to maintain systemic lipid homeostasis. The Gene Ontology term GO:0097006, regulation of plasma lipoprotein particle levels, captures any process involved in maintaining the internal levels of these particles within an organism. This includes the synthesis and secretion of triglyceride-rich VLDL, the remodeling of HDL, the clearance of LDL via receptors, and the modulation of lipoprotein(a). Researchers study this term because dysregulated lipoprotein levels are directly linked to cardiovascular disease, metabolic syndrome, and renal disorders. The pathways are complex, involving hepatic and intestinal production, intravascular lipolysis, and reverse cholesterol transport. Understanding the molecular mechanisms offers opportunities for therapeutic intervention and biomarker discovery.
regulation of plasma lipoprotein particle levels At A Glance
| GO ID | GO:0097006 |
|---|---|
| GO term | regulation of plasma lipoprotein particle levels |
| Ontology | biological_process |
| Synonym | plasma lipoprotein particle homeostasis |
| Major function | Maintenance of internal levels of plasma lipoprotein particles |
| Related particles | VLDL, LDL, HDL, Lp(a), chylomicrons |
| Key tissues | Liver, intestine, adipose tissue, macrophages |
| Disease relevance | Atherosclerosis, nephrotic syndrome, obesity, dyslipidemia |
What Is GO:0097006?
GO:0097006, regulation of plasma lipoprotein particle levels, is defined as any process involved in the maintenance of internal levels of plasma lipoprotein particles within an organism. It is a biological process that encompasses the synthesis, secretion, remodeling, and clearance of lipoproteins such as VLDL, LDL, HDL, and Lp(a). The synonym plasma lipoprotein particle homeostasis reflects the balance between production and removal. This term does not refer to a single gene or protein but rather to the collective regulatory mechanisms that keep lipoprotein concentrations within physiological ranges.
Why Is regulation of plasma lipoprotein particle levels Important in Cell Biology?
Regulation of plasma lipoprotein particle levels is critical because lipoproteins are the primary carriers of cholesterol and triglycerides in the bloodstream, and their imbalance is a major risk factor for cardiovascular disease. The process integrates hepatic and intestinal lipid metabolism, intravascular remodeling, and receptor-mediated clearance. Defects in this regulation contribute to atherosclerosis, nephrotic syndrome, and obesity-related dyslipidemia. Moreover, therapeutic strategies that lower LDL or modulate HDL and Lp(a) rely on understanding these regulatory mechanisms. Thus, GO:0097006 provides a framework for studying lipid transport and its impact on human health.
• Maintains systemic lipid homeostasis by balancing lipoprotein production and clearance.
• Dysregulation leads to atherosclerosis and cardiovascular disease.
• Nephrotic syndrome causes severe dyslipidemia via altered lipoprotein metabolism.
• Obesity is associated with increased VLDL secretion and altered HDL levels.
• Lp(a) is an independent risk factor for cardiovascular disease.
• HDL function, beyond cholesterol efflux, influences mitochondrial and endothelial health.
• Intracellular cholesterol transport affects lipoprotein assembly and secretion.
• Targeting lipoprotein regulation is a cornerstone of lipid-lowering therapies.
• CRISPR screens can identify novel regulators of lipoprotein levels.
• Modeling lipoprotein disorders in cells and animals aids drug discovery.
What Happens During regulation of plasma lipoprotein particle levels?
VLDL Assembly and Secretion
In simple terms: The liver packages triglycerides and cholesterol into VLDL particles that are released into the blood.
VLDL biogenesis involves the co-translational lipidation of APOB by microsomal triglyceride transfer protein (MTTP) in the endoplasmic reticulum, followed by fusion with lipid droplets and secretion. This step is regulated by the availability of lipids and apolipoproteins, and it determines the number of triglyceride-rich particles entering circulation. Impaired VLDL secretion leads to hepatic steatosis, while overproduction contributes to hypertriglyceridemia.
Intravascular Remodeling and Lipolysis
In simple terms: Enzymes in the blood break down triglycerides in lipoproteins, converting VLDL to LDL and remodeling HDL.
Lipoprotein lipase (LPL) hydrolyzes triglycerides in chylomicrons and VLDL, releasing free fatty acids for tissue uptake. Cholesterol ester transfer protein (CETP) transfers cholesteryl esters from HDL to APOB-containing particles in exchange for triglycerides, while phospholipid transfer protein (PLTP) remodels HDL. These remodeling steps determine the final lipid composition and particle size.
Receptor-Mediated Clearance
In simple terms: Cells take up lipoproteins through specific receptors, removing them from the bloodstream.
The LDL receptor (LDLR) mediates endocytosis of LDL, and its expression is regulated by intracellular cholesterol levels via SREBP-2. Scavenger receptor BI (SR-B1) facilitates selective cholesterol uptake from HDL in the liver and steroidogenic tissues. Other receptors, such as LRP1 and VLDLR, contribute to remnant clearance. Defects in these receptors cause familial hypercholesterolemia and dyslipidemia.
Reverse Cholesterol Transport and HDL Function
In simple terms: HDL picks up excess cholesterol from tissues and brings it back to the liver for disposal.
HDL particles accept cholesterol from macrophages via ABCA1 and ABCG1, and the enzyme LCAT esterifies cholesterol to maintain the gradient. HDL also carries antioxidants and modulates mitochondrial function in endothelial cells. The regulation of HDL levels involves APOA1 synthesis, remodeling by CETP and PLTP, and catabolism via SR-B1 and kidney clearance.
Lipoprotein(a) Metabolism
In simple terms: Lp(a) is a special lipoprotein whose levels are largely genetically determined and linked to heart disease.
Lp(a) consists of an LDL-like particle covalently bound to apolipoprotein(a). Its plasma concentration is primarily regulated by the LPA gene, and it contributes to atherosclerosis through pro-inflammatory and pro-thrombotic effects. Therapies targeting Lp(a) are under development, highlighting the importance of understanding its regulation.
Key Genes Involved in GO:0097006 regulation of plasma lipoprotein particle levels
The following genes encode proteins that directly participate in the regulation of plasma lipoprotein particle levels, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Core structural protein of VLDL, LDL, and Lp(a) | Target for knockout to study VLDL secretion |
| APOA1 | Major protein of HDL | Knockout models to study HDL biogenesis |
| APOE | Ligand for receptor-mediated clearance of remnants | Knockout mice develop hypercholesterolemia |
| MTTP | Lipidates APOB during VLDL assembly | Inhibition reduces VLDL secretion |
| LPL | Hydrolyzes triglycerides in VLDL and chylomicrons | Defects cause hypertriglyceridemia |
| CETP | Transfers cholesteryl esters between lipoproteins | Inhibition raises HDL and lowers LDL |
| PLTP | Remodels HDL and transfers phospholipids | Knockout alters HDL size |
| LCAT | Esterifies cholesterol on HDL | Deficiency causes fish-eye disease |
| LDLR | Mediates LDL clearance | Mutations cause familial hypercholesterolemia |
| SR-B1 | Selective cholesterol uptake from HDL | Knockout increases HDL cholesterol |
| ABCA1 | Effluxes cholesterol to APOA1 | Mutations cause Tangier disease |
| ABCG1 | Effluxes cholesterol to HDL | Regulates macrophage cholesterol |
| LPA | Encodes apolipoprotein(a) | Determines Lp(a) levels |
| PCSK9 | Promotes LDLR degradation | Inhibition lowers LDL |
| SREBP2 | Regulates cholesterol synthesis and LDLR | Feedback control of lipoprotein uptake |
| NR1H3 | Liver X receptor, regulates cholesterol efflux | Target for HDL modulation |
| PPARG | Regulates adipocyte lipid metabolism | Linked to obesity dyslipidemia |
How Is regulation of plasma lipoprotein particle levels Regulated?
The regulation of plasma lipoprotein particle levels is controlled at multiple levels, including transcriptional, post-transcriptional, and post-translational mechanisms. Intracellular cholesterol levels regulate SREBP-2, which controls LDLR and cholesterol synthesis genes. The liver X receptor (LXR) pathway induces ABCA1 and ABCG1 to promote cholesterol efflux. Hormonal signals such as insulin and estrogen influence VLDL secretion and LPL activity. Additionally, genetic variants in APOB, APOE, LPA, and PCSK9 significantly affect lipoprotein concentrations. Understanding these regulatory layers is essential for developing targeted therapies.
regulation of plasma lipoprotein particle levels and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia | Knockout hepatocytes or knock-in mice |
| APOB | Hypobetalipoproteinemia | Knockout cell lines |
| LPA | Elevated Lp(a) and cardiovascular risk | Overexpression in hepatocytes |
| ABCA1 | Tangier disease | Knockout macrophages |
| CETP | Altered HDL levels | Knockout or transgenic models |
Atherosclerotic Cardiovascular Disease
Elevated LDL cholesterol and Lp(a) are causal risk factors for atherosclerosis. Dysregulation of lipoprotein levels, including increased VLDL secretion and impaired clearance, promotes plaque formation. Therapies that lower LDL, such as statins and PCSK9 inhibitors, reduce cardiovascular events. HDL function, beyond cholesterol efflux, also influences endothelial health and mitochondrial function.
Nephrotic Syndrome
Nephrotic syndrome is characterized by severe dyslipidemia, with elevated LDL, VLDL, and Lp(a) levels. Mechanisms include increased hepatic lipoprotein synthesis and decreased clearance due to altered lipoprotein lipase activity. Managing dyslipidemia in these patients is important to reduce cardiovascular risk.
Obesity and Metabolic Syndrome
Obesity is associated with increased VLDL secretion, hypertriglyceridemia, and low HDL cholesterol. Insulin resistance contributes to overproduction of large VLDL and altered HDL remodeling. Weight loss and insulin sensitizers improve lipoprotein profiles.
Genetic Disorders of Lipoprotein Metabolism
Mutations in LDLR, APOB, or PCSK9 cause familial hypercholesterolemia, while defects in ABCA1 cause Tangier disease. LPA variants determine Lp(a) levels and cardiovascular risk. These monogenic disorders provide insights into the regulation of plasma lipoprotein particles.
From regulation of plasma lipoprotein particle levels-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate VLDL secretion? | CRISPR knockout in HepG2 or primary hepatocytes |
| Does mutation Y affect LDLR function? | Point mutation knock-in in cell lines |
| Can overexpression of gene Z increase HDL? | Stable overexpression in APOA1-expressing cells |
| What is the role of Lp(a) in atherosclerosis? | LPA knock-in mouse models |
| How does gene W affect cholesterol efflux? | Knockout in macrophages followed by efflux assay |
| Does SNP in gene V alter lipoprotein levels? | CRISPR knock-in of SNP in hepatocytes |
How to Study the regulation of plasma lipoprotein particle levels Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for lipoprotein secretion | Identify novel regulators |
| FPLC | Lipoprotein particle size distribution | Phenotype of KO models |
| ELISA | Apolipoprotein concentrations | Quantify APOB, APOA1, Lp(a) |
| Fluorescence microscopy | Cellular uptake and trafficking | Study LDLR endocytosis |
| RNA-seq | Transcriptional changes | Pathway analysis in KO cells |
| Proteomics | Protein abundance and modifications | Identify signaling changes |
| Cholesterol efflux assay | HDL function | Evaluate ABCA1/ABCG1 activity |
| Lipidomics | Lipid species profiling | Assess lipid composition |
CRISPR Screens for Lipoprotein Regulators
Genome-wide CRISPR knockout or activation screens can identify genes that alter lipoprotein secretion or uptake in hepatocyte cell lines. These screens use readouts such as APOB or APOA1 secretion, or fluorescent lipid analogs. Hits are validated by individual knockout and lipid assays.
Biochemical Assays for Lipoprotein Quantification
Lipoprotein levels can be measured by enzymatic assays for cholesterol and triglycerides, or by FPLC to separate particle classes. ELISA for apolipoproteins (APOB, APOA1, Lp(a)) provides specific quantification. These methods are essential for phenotyping CRISPR models.
Imaging and Trafficking Studies
Fluorescently labeled lipoproteins or tagged apolipoproteins can be used to track uptake and trafficking in live cells. Confocal microscopy reveals colocalization with endosomal markers. This helps dissect receptor-mediated clearance mechanisms.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics of CRISPR models can reveal global changes in lipid metabolism pathways. Phosphoproteomics can identify signaling changes affecting lipoprotein secretion. These approaches provide systems-level insights into regulation.
How CRISPR Can Be Used to Study GO:0097006 regulation of plasma lipoprotein particle levels
Knockout
CRISPR knockout of genes such as APOB, MTTP, or LDLR in hepatocyte cell lines abolishes or reduces lipoprotein secretion and uptake, providing causal evidence for their role in GO:0097006. Knockout models are also used to validate hits from genome-wide screens.
Point Mutation
Introducing disease-associated point mutations (e.g., in LDLR or APOB) via CRISPR base editing or HDR allows study of functional consequences on lipoprotein clearance. These models mimic familial hypercholesterolemia alleles.
Knock-in
Knock-in of human LPA or APOE variants into cell lines or mice enables investigation of Lp(a) metabolism and APOE isoform-specific effects on lipoprotein levels. Tagged knock-in (e.g., GFP-APOB) facilitates tracking of lipoprotein secretion.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like APOA1, LCAT, or ABCA1 increases HDL biogenesis and cholesterol efflux, allowing gain-of-function studies. Overexpression models help identify rate-limiting steps in lipoprotein regulation.
How EDITGENE Supports regulation of plasma lipoprotein particle levels Research
Researchers studying regulation of plasma lipoprotein particle levels-related genes often need to determine whether a candidate gene is causally involved in lipoprotein metabolism. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of plasma lipoprotein particle levels research.
Frequently Asked Questions About regulation of plasma lipoprotein particle levels
What is GO:0097006?
GO:0097006 is the Gene Ontology term for regulation of plasma lipoprotein particle levels, defined as any process involved in maintaining the internal levels of plasma lipoprotein particles within an organism.
What genes are involved in regulation of plasma lipoprotein particle levels?
Key genes include APOB, APOA1, APOE, MTTP, LPL, CETP, PLTP, LCAT, LDLR, SR-B1, ABCA1, ABCG1, LPA, and PCSK9, among others.
How is plasma lipoprotein particle levels regulated?
It is regulated through VLDL assembly and secretion, intravascular remodeling by lipases and transfer proteins, receptor-mediated clearance, and reverse cholesterol transport.
What diseases are associated with dysregulation of plasma lipoprotein particle levels?
Atherosclerosis, nephrotic syndrome, obesity, metabolic syndrome, and familial hypercholesterolemia are linked to dysregulated lipoprotein levels.
What is the role of HDL in plasma lipoprotein particle levels?
HDL mediates reverse cholesterol transport, carries antioxidants, and influences mitochondrial function; its levels are regulated by APOA1, LCAT, CETP, and SR-B1.
How can CRISPR be used to study regulation of plasma lipoprotein particle levels?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes in lipoprotein secretion, remodeling, and clearance.
What is lipoprotein(a) and how is it regulated?
Lp(a) is an LDL-like particle bound to apolipoprotein(a), primarily regulated by the LPA gene, and is a risk factor for cardiovascular disease.
What experimental models are used to study plasma lipoprotein regulation?
Hepatocyte cell lines (HepG2, Huh7), primary hepatocytes, macrophages, and mouse models are commonly used, often with CRISPR engineering.
How does nephrotic syndrome affect lipoprotein levels?
Nephrotic syndrome causes dyslipidemia with elevated LDL, VLDL, and Lp(a) due to increased synthesis and decreased clearance.
What methods measure plasma lipoprotein particle levels?
Enzymatic assays, FPLC, ELISA for apolipoproteins, and lipidomics are standard methods to quantify lipoprotein particles.
Conclusion
GO:0097006 regulation of plasma lipoprotein particle levels is a central biological process that maintains lipid homeostasis and whose dysregulation underlies major human diseases. The integration of apolipoprotein synthesis, intravascular remodeling, receptor clearance, and reverse cholesterol transport determines the levels of VLDL, LDL, HDL, and Lp(a). CRISPR-based models are powerful tools to dissect these mechanisms and identify therapeutic targets. Understanding this process is essential for developing strategies to prevent and treat cardiovascular and metabolic disorders.
References
- 1. van Zwol W et al.. 2024. VLDL Biogenesis and Secretion: It Takes a Village.. Circ Res 134(2):226-244 PMID: 38236950
- 2. Agrawal S et al.. 2018. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.. Nat Rev Nephrol 14(1):57-70 PMID: 29176657
- 3. Vinci P et al.. 2023. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.. Int J Environ Res Public Health 20(18) PMID: 37754581
- 4. Hovingh GK et al.. 2015. HDL re-examined.. Curr Opin Lipidol 26(2):127-32 PMID: 25692348
- 5. Rye KA et al.. 2014. Regulation of high-density lipoprotein metabolism.. Circ Res 114(1):143-56 PMID: 24385508
- 6. White CR et al.. 2017. High-Density Lipoprotein Regulation of Mitochondrial Function.. Adv Exp Med Biol 982:407-429 PMID: 28551800
- 7. Fielding CJ et al.. 1997. Intracellular cholesterol transport.. J Lipid Res 38(8):1503-21 PMID: 9300773
- 8. Després JP. 1994. Dyslipidaemia and obesity.. Baillieres Clin Endocrinol Metab 8(3):629-60 PMID: 7980350
